Nabriva Therapeutics (NBRV) News Today → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free NBRV Stock Alerts Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.comamericanbankingnews.com - May 3 at 2:28 AMNabriva Therapeutics PLC NBRVFmorningstar.com - April 13 at 11:36 PMArbutus Biopharma Corporation: Arbutus Appoints Two New Executivesfinanznachrichten.de - July 11 at 1:19 PMNBRV - Nabriva Therapeutics plcfinance.yahoo.com - May 26 at 2:12 AMmarketbeat.com - March 27 at 9:36 AMBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029marketwatch.com - February 28 at 1:25 AMNBRV Nabriva Therapeutics plcseekingalpha.com - February 25 at 2:19 AMNabriva Therapeutics Provides Corporate Updatefinance.yahoo.com - January 6 at 7:16 AMNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Datamarketwatch.com - November 28 at 9:18 PMNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosismarkets.businessinsider.com - November 28 at 9:18 PMNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Upmarkets.businessinsider.com - November 28 at 9:18 PMNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentbizjournals.com - November 28 at 9:18 PMNabriva gains after announcing Phase 1 data for cystic fibrosis candidateseekingalpha.com - November 28 at 9:18 PMNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosisfinance.yahoo.com - November 28 at 9:18 PMNabriva's stock is up after sharing antibiotic newsfinance.yahoo.com - November 28 at 9:18 PMNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentfinance.yahoo.com - November 28 at 9:18 PMMontgomery County biopharmaceutical firm reducing workforce by 40%finance.yahoo.com - November 10 at 10:09 PMNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Updatetechnews.tmcnet.com - November 10 at 5:09 PMNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - November 10 at 5:09 PMNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022finance.yahoo.com - November 7 at 8:33 AMNabriva Therapeutics plc (NASDAQ:NBRV) Sees Significant Drop in Short Interestmarketbeat.com - September 18 at 2:10 AMNabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst Upgrademarketbeat.com - September 16 at 10:27 AMNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Splitfinance.yahoo.com - September 15 at 11:44 AMAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buyfinance.yahoo.com - September 14 at 3:55 PMNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 7:13 AMNabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Up 24.1% in Julymarketbeat.com - August 15 at 12:20 AMNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosismarketwatch.com - August 12 at 5:16 AMNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosisfinance.yahoo.com - August 11 at 2:14 PMNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 4 at 12:00 AMNabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Updatefinance.yahoo.com - August 3 at 7:00 PMNabriva Therapeutics (NBRV) to Release Quarterly Earnings on Wednesdaymarketbeat.com - July 27 at 7:22 AMNabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022finance.yahoo.com - July 20 at 7:59 PMNabriva Inks Exclusive Distribution Agreement With Er-Kimmarkets.businessinsider.com - July 18 at 7:53 AMNabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticalsfinance.yahoo.com - July 18 at 7:53 AMNabriva Therapeutics plc (NASDAQ:NBRV) Sees Large Decline in Short Interestmarketbeat.com - May 31 at 5:42 PM$9.47 Million in Sales Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quartermarketbeat.com - May 25 at 3:10 AMNabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - May 13 at 4:10 PMNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 8 at 12:11 PMNabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Updatefinance.yahoo.com - May 5 at 7:07 PMNabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in USseekingalpha.com - May 5 at 9:06 AMNabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026finance.yahoo.com - May 5 at 9:06 AMA Preview Of Nabriva Therapeutics's Earningsbenzinga.com - May 4 at 10:30 PMNabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022finance.yahoo.com - May 2 at 6:04 PMNabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosisfinance.yahoo.com - April 11 at 4:21 PMNorthland Securities slashes Nabriva Therapeutics' price targetseekingalpha.com - March 30 at 12:26 PMNabriva Therapeutics (NASDAQ:NBRV) Price Target Cut to $2.00marketbeat.com - March 30 at 9:21 AMNabriva Therapeutics plc 2021 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 29 at 10:23 PMNabriva Therapeutics Earnings, Revenue Miss in Q1investing.com - March 29 at 8:54 PMNabriva 4Q results indicate slowdown in topline growthseekingalpha.com - March 29 at 8:54 PMNabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Updatefinance.yahoo.com - March 29 at 8:54 PM Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide NBRV Media Mentions By Week NBRV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBRV News Sentiment▼0.000.38▲Average Medical News Sentiment NBRV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBRV Articles This Week▼10▲NBRV Articles Average Week Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AADI News GANX News RMTI News BOLT News IMRX News CKPT News CARA News LEXX News UNCY News EQ News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBRV) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
